Five of our most advanced and high-potential clinical and preclinical assets are being progressed to their next inflection points.

  • Target
  • Chemistry and Lead Optimisation
  • Preclinical
  • Phase I
  • Phase II
BEN-8744 Ulcerative Colitis
Target: PDE10
BEN-28010 Glioblastoma Multiforme
Target: CHK1
BEN-34712 ALS
Target: RAR⍺β
Parkinson's disease
Target: Novel Target
Fibrosis
Target: Novel Target

Regular re-evaluation of 10+ BenevolentAI paused programmes and potential new pipeline entries:

  • demonstrates utility to find novel insights previously not connect in the literature; and
  • develop and advance unique and differentiated molecules.